Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years-Reference-Cited by-同舟云学术

Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years

Published:2019-08-01 Issue:4 Volume:81 Page:473-480
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Bwakura Dangarembizi Mutsa,Samson Pearl,Capparelli Edmund V.,Moore Carolyn Bolton,Jean-Philippe Patrick,Spector Stephen A.,Chakhtoura Nahida,Benns Alex,Zimmer Bonnie,Purdue Lynette,Jackson Chivon,Wallis Carole,Libous Jennifer L.,Chadwick Ellen G.,

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference24 articles.

1. The impact of HIV and antiretroviral therapy on TB risk in children: a systematic review and meta-analysis;Dodd;Thorax.,2017

2. Dose adjustment of the nonnucleoside reverse transcriptase inhibitors (NNRTIs) during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all;Kwara;Expert Opin Drug Metab Toxicol.,2010

3. Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers;Cho;Drug Metab Pharmacokinet.,2016

4. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results;Manosuthia;AIDS.,2006

5. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis;López-Cortés;Clin Pharmacokinet.,2002

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Human immunodeficiency virus/acquired immunodeficiency syndrome in the infant;Remington and Klein's Infectious Diseases of the Fetus and Newborn Infant;2025

2. Brief Report: Suboptimal Lopinavir Exposure in Infants on Rifampicin Treatment Receiving Double-dosed or Semisuperboosted Lopinavir/Ritonavir: Time for a Change;JAIDS Journal of Acquired Immune Deficiency Syndromes;2023-04-01

3. Pediatric AIDS–Therapeutic Successes Built on a Foundation of Pediatric Clinical Pharmacology with Pharmacokinetic-Pharmacodynamic Modeling;The Journal of Pediatric Pharmacology and Therapeutics;2022-07-01

4. Impact of CYP2B6 genotype, TB therapy and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age;AIDS;2021-12-06

5. Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review;Journal of Antimicrobial Chemotherapy;2020-08-12